Fig. 3From: FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinomaRECIST1.1 and PERCIST1.0 assessments from time of cemiplimab commencement. This figure highlights the relevant response assessments as well as the most recent RECIST1.1 assessment. CMR, complete metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease. CR, complete response; PR, partial response. SD, stable disease. PD, progressive diseaseBack to article page